Sandra P. Susanibar-Adaniya

Sandra P. Susanibar-Adaniya serves as Assistant Professor of Medicine in the Hematology-Oncology division at the Perelman School of Medicine, University of Pennsylvania. She practices clinically at the Abramson Cancer Center within the Hospital of the University of Pennsylvania, specializing in multiple myeloma and immunotherapy management for adult patients. Her institutional affiliations include active roles in the U.S. Myeloma Immunotherapy Consortium and Penn Medicine's hematology research infrastructure.

Education and training:

• Medical Degree: National University of San Marcos
• Residency: Hospital Nacional Edgardo Rebagliati Martins
• Residency: University of Arkansas for Medical Sciences
• Fellowship: Hospital of the University of Pennsylvania (Hematology-Oncology)

Dr. Susanibar-Adaniya's research focuses on optimizing immunotherapies for multiple myeloma, with particular emphasis on real-world outcomes of teclistamab and CAR-T cell therapies. Her work systematically addresses critical gaps in treatment access and safety across diverse populations, including elderly patients, racial/ethnic minorities, and those with comorbid conditions like renal impairment. She leads multi-center investigations into therapy-related complications and demographic disparities, translating findings into clinical practice improvements through high-impact publications.

Analysis of her 2024-2025 publications reveals a dominant focus on teclistamab applications across complex clinical scenarios. Key thematic clusters include demographic disparity research (25% of output), specialized population management (elderly/renal impairment; 30%), immunotherapy complication profiles (20%), and cross-disease therapeutic applications (15%). Her work consistently leverages multi-center consortium data to generate real-world evidence influencing clinical decision-making.

Scientific contributions:

• 10 peer-reviewed publications in 2024-2025
• Leadership in U.S. Myeloma Immunotherapy Consortium
• Focus on health equity in advanced myeloma therapeutics
• High-impact journal placements including Blood Cancer Journal and Journal for ImmunoTherapy of Cancer

Dr. Susanibar-Adaniya maintains active clinical research programs through the Abramson Cancer Center, with current investigations centered on immunotherapy safety optimization and disparity reduction. Her mentorship focuses on translational research methods for hematology fellows, though formal student advising isn't documented. Funding appears consortium-driven through multi-institutional collaborations rather than individual R01 grants.

As a core member of Penn's hematology-oncology division, she contributes to both clinical service delivery and research infrastructure. Her work with the U.S. Myeloma Immunotherapy Consortium represents a significant collaborative platform for generating real-world evidence that directly informs treatment guidelines for novel immunotherapies in complex myeloma cases.